Experimental mRNA cancer vaccine shows promise in major trial, cutting recurrence risk

A new experimental personalized mRNA cancer vaccine, developed by Moderna and Merck, has shown significant success in a major Phase 3 clinical trial for high-risk melanoma. The vaccine, known as intismeran autogene (V940 or mRNA-4157), when administered alongside Merck's immunotherapy drug Keytruda (pembrolizumab) after surgery, reduced the risk of cancer recurrence or death by 42%. Additionally, the combination therapy was found to reduce the risk of the cancer spreading by 38%.

This large-scale trial, which involved over 1,100 patients, represents a notable advancement in personalized cancer treatment, being the first Phase 3 study of an individualized neoantigen therapy to demonstrate such a benefit over Keytruda alone. The personalized mRNA vaccine works by instructing the patient's immune system to recognize and target unique mutations present in their specific tumor, complementing Keytruda's action of unleashing the immune system against cancer cells.

While the full detailed results were recently released and are slated for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, initial reports indicate minimal side effects, including fatigue and fever. The positive outcomes have led the developers to engage with regulatory authorities, hinting at potential filings for approval soon, and the technology is also being investigated for other cancer types, such as lung and pancreatic cancers.